Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from FDA

Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Benzinga

Married couple whose home was bursting with truckloads of illegal sex pills sentenced

Eduard Yusupov and Diana Fuzailov sold sexual enhancement products online via their company Love Potion, Inc., claiming them to be made from natural ingredients

The Independent UK

Congress Sounds Alarm Over Illegal Weight-Loss Drug Imports From China

In a letter to the U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Friday, over 80 bipartisan members asked the agency to stop counterfeit and copycat versions of GLP-1 drugs like Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide) and Eli Lilly and Co.’s (NYSE:LLY) Zepbound from flooding the market.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales

In June, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.'s (NASDAQ:GILD) Yeztugo (lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the U.S. for people who need or…

Benzinga

Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy

On Friday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the conditional marketing authorisation (CMA) for Elevidys (delandistrogene moxeparvovec) for ambulatory individuals aged three to seven years with Duchenne muscular dystrophy (DMD).

Benzinga

Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Friday recommending Eli Lilly and Co.’s (NYSE:LLY) donanemab for early symptomatic Alzheimer’s disease in adults with confirmed amyloid pathology who are apolipoprotein E ε4 (ApoE4) heterozygotes or non-carriers.

Benzinga

9 DIY Remedies That Medical Boards Are Warning Against

DIY health hacks flood social media and blogs with promises of miracle cures and quick fixes. From homemade detox teas to sketchy dental work, these trends often spread faster than facts can catch up. But while some may seem harmless, medical boards across the country are issuing clear warnings.

Everybody Loves Your Money

Read news from The Economist, FT, and more,
with one subscription

RFK Jr wants bright artificial dyes out of food. Are Americans ready to let go?

In the past, US consumers have resisted their favorite foods changing to natural dyes. Attitudes might shift if Maha converts the entire industry

The Guardian - US

9 Products Labeled ‘Natural’ That Still Contain Controversial Ingredients

The word “natural” on a product label can be powerfully persuasive, making consumers feel like they are choosing a healthier, safer, and more wholesome option. However, the Food and Drug Administration (FDA) has no formal, regulated definition for the term “natural.” This allows manufacturers to use it as a marketing…

Grocery Coupon Guide

GSK's Blood Cancer Drug Review Extended As FDA Seeks More Data

The US Food and Drug Administration (FDA) on Wednesday extended the review period for the Biologics License Application (BLA) for GSK plc’s (NYSE:GSK) Blenrep combinations for relapsed or refractory multiple myeloma patients who have received at least one prior line of therapy.

Benzinga

The Truth About “Organic”: 8 Common Kid Snacks With Dangerous Allergens

Image source: 123rf.com

Kids Ain't Cheap

15 Best Vagus Nerve Stimulation Devices in 2025

Stress and sleepless nights can wear anyone down

inkl

Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revise Label

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced Monday it will voluntarily and temporarily pause all U.S. shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, effective July 22.

Benzinga

What's Going On With Moderna Stock Wednesday?

Moderna Inc.’s (NASDAQ:MRNA) stock has surged approximately 37% in the last month but has dipped around 15% year to date.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Americans Are Turning To DIY Weight Loss Injections to Dodge $1,000+ Monthly Drug Costs

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ingredients from China, Reuters reported recently.

Roll Call

Kennedy's mental health drug skepticism lands at FDA panel - Roll Call

Democrats have accused Robert Kennedy Jr. of making claims without scientific research to back them and say his claims are dangerous.

International Business Times UK

Listeria Contamination Concerns Spark US Tuna Recall: How Serious Is Listeriosis?

Dozens of tuna salad products have been recalled from stores in seven US states due to possible listeria contamination, a bacteria that can lead to deadly infections like listeriosis.

Benzinga

EXCLUSIVE: Intelligent Bio Solutions' New Data Confirms Ability To Detect Trace Sweat Volumes At Ultra-Micro Level

Intelligent Bio Solutions Inc. (NASDAQ:INBS) on Wednesday announced the collection of new data that further reinforces the security and performance of its Intelligent Fingerprinting Drug Screening System, strengthening its FDA 510(k) submission.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study

Abivax SA (NASDAQ:ABVX) stock is skyrocketing on Wednesday after the clinical-stage biotechnology company announced overwhelmingly positive topline results from its Phase 3 ABTECT-1 (Study 105) and ABTECT-2 (Study 106) 8-week induction trials for oral obefazimod (ABX464) in adult patients with moderately to severely active ulcerative colitis.

Benzinga

OFA Group Pops Nearly 70% After Hours As Bitcoin Strategy Comes In Focus

OFA Group (NASDAQ:OFAL) experienced an increase in its stock value after hours on Tuesday. The company’s stock value surged by 69.94% to $2.94.

International Business Times

More than Skin Deep: Exploring Rejuvaskin's Mission to Redefine Skin Health

For Chris Christenberry, CEO of Rejuvaskin, skin health goes beyond skincare buzzwords and marketing trends, but is rooted in medical necessity.

The Independent UK

Sweetening soft drinks: What to know about sugar, high-fructose corn syrup and their alternatives

President Donald Trump teased the announcement last week, but Coca-Cola finally confirmed it Tuesday: a version of Coke’s trademark cola sweetened with cane sugar will be released in the U.S. this fall

Barchart

The FDA Just Approved Juul’s E-Cigarettes. Does That Make Altria Stock a Buy Here?

Altria was an earlier investor in Juul. Will its FDA approval be good news for the Altria’s NJOY brand?

Benzinga

FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division

The U.S. Food and Drug Administration appointed George F. Tidmarsh on Monday as director of the Center for Drug Evaluation and Research (CDER).

Benzinga

Drug Innovation At Risk By Trump Budget, Says Congressional Budget Office

According to a new U.S. Congressional Budget Office analysis, President Donald Trump’s 2026 budget plan proposes cuts to the National Institutes of Health that could significantly reduce the number of new drugs entering the market.

1 … 46 47 48 49

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.